Professor David Keegan:

Yes, it is over three years. It is more upfront because of the equipment costs and then that sort of dips off as we come off the transformation costs, so it is actually coming down. The finance team does not want to project much beyond that because one of the issues we have is if we are very successful and, say, quadruple the number of cataract treatment, there are consumable costs in there. We do not want to come back and feel like we were misleading anybody. If our level of activity goes up, so will the costs. What we would like to be held to account about, is perhaps not the overall cost, but the per unit cost. If we come back and the ask is more than that, the fair questions back to us would be how much activity we had done, how many more patients have been seen, how many more surgeries have been done and how much more sight has been managed, rescued or saved. We will absolutely be held account on that regard.